DGAP-News: World Street Fundamentals: A Brighter Decade Ahead for Biotech - In-Depth Research Featuring GlaxoSmithKline and NPS Pharmaceuticals
ID: 388821
Update
World Street Fundamentals: A Brighter Decade Ahead for Biotech -
In-Depth Research Featuring GlaxoSmithKline and NPS Pharmaceuticals
15.04.2011 / 15:04
---------------------------------------------------------------------
A Brighter Decade Ahead for Biotech - In-Depth Research Featuring
GlaxoSmithKline and NPS Pharmaceuticals
Today, www.WorldStreetFundamentals.com released its industry report
highlighting GlaxoSmithKline (NYSE:GSK) and NPS Pharmaceuticals, Inc.
(NASDAQ:NPSP). Full fundamental and technical analysis is available at
www.WorldStreetFundamentals.com/Reports.php.
The global pharmaceutical market is expected to experience wide changes,
with trends growing towards the Asia-Pacific region. A favorable regulatory
environment has started to emerge in India, China, Malaysia, South Korea
and Indonesia; drawing the attention of larger API product providers. This
new competition within an already fast-paced economy has closed the gap
between product cost and disposable income of consumers- a change that is
expected to drive long-term growth within the global marketplace.
Global pharmaceutical market sales are expected to grow at a 4 - 7%
compound annual growth rate (CAGR) through 2013, largely driven via growing
access to health-care in emerging economic regions. Short-term growth
within the sector will be fueled by the US market, as it remains the
largest pharmaceutical market in the world. A large focus on R&D in
biotechnology, special drugs and generic drugs will remain a strong
catalyst to meet 2011 targets of $315 billion dollar in sales volume within
the United States alone.
World Street Fundamentals has highlighted GlaxoSmithKline for its recent
FDA approval of Horizant (gabapentin enacarbil) Extended-Release Tablets
for the treatment of moderate-to-severe primary Restless Legs Syndrome in
adults. It is the first medication in its class to be approved for the
treatment of moderate-to-severe primary Restless Legs Syndrome. Discovered
and developed by XenoPort, Horizant is a new chemical entity that utilizes
the body's nutrient transport mechanisms that are believed to facilitate
its absorption into the body. The entire report on GlaxoSmithKline
(NYSE:GSK) is available here:
www.WorldStreetFundamentals.com/ViewFullReport.245.php.
World Street has highlighted NPS Pharmaceuticals for its focus on bringing
biopharmaceuticals to patients with rare disorders and few, if any,
therapeutic options. The company is advancing two Phase 3 registration
programs, GATTEX(R) (teduglutide) in short bowel syndrome (SBS) and NPSP558
(parathyroid hormone 1-84 [rDNA origin] injection) in hypoparathyroidism.
NPS complements its proprietary programs with a royalty-based portfolio of
products and product candidates that includes agreements with Amgen, Kyowa
Hakko Kirin, Nycomed, and Ortho-McNeil Pharmaceutical. The entire report on
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) is available here:
www.WorldStreetFundamentals.com/ViewFullReport.138.php.
About World Street
World Street Fundamentals is an online portal for professionals, investors
and new-comers to the markets to find in depth comprehensive research and
research tools to help guide you through the ever changing financial
markets around the world.
Contact:
Adam Redford
editor@worldstreetfundamentals.com
www.WorldStreetFundamentals.com
End of Corporate News
---------------------------------------------------------------------
15.04.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
120215 15.04.2011Unternehmensinformation / Kurzprofil:
Datum: 15.04.2011 - 15:04 Uhr
Sprache: Deutsch
News-ID 388821
Anzahl Zeichen: 4453
Kontakt-Informationen:
Kategorie:
Wirtschaft (allg.)
Diese Pressemitteilung wurde bisher 220 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: World Street Fundamentals: A Brighter Decade Ahead for Biotech - In-Depth Research Featuring GlaxoSmithKline and NPS Pharmaceuticals"
steht unter der journalistisch-redaktionellen Verantwortung von
World Street Fundamentals (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
DGAP-News: World Street Fundamentals / Schlagwort(e): Research Update Comprehensive Research Featuring Daimler and Volkswagen - Global Automakers Rebuild Competitive Landscape 21.04.2011 / 08:00 --------------------------------------------------------------------- Comprehensive Research Featuring
DGAP-News: World Street Fundamentals: Shift within Dynamics of Waste Management - In-Depth Research Featuring Waste Management and Republic Services ...
DGAP-News: World Street Fundamentals / Key word(s): Study/Research Update World Street Fundamentals: Shift within Dynamics of Waste Management - In-Depth Research Featuring Waste Management and Republic Services 15.04.2011 / 15:31 -------------------------------------------------------------------
DGAP-News: World Street Fundamentals: Focus on Strategy within Technology Reap Rewards - In-Depth Research Featuring 3D Systems Corporation and Identive Group, Inc. ...
DGAP-News: World Street Fundamentals / Key word(s): Study/Research Update World Street Fundamentals: Focus on Strategy within Technology Reap Rewards - In-Depth Research Featuring 3D Systems Corporation and Identive Group, Inc. 15.04.2011 / 15:25 ---------------------------------------------------
Weitere Mitteilungen von World Street Fundamentals
Superman hat umgeschult ...
München. Interim Manager galten jahrelang als Supermänner, die vor allem krisengeschüttelte Firmen retten und sanieren. Wie der AIMP (Arbeitskreis Interim Management Provider) nun in seiner aktuellen Studie vorstellt, hat sich dieses Bild grundlegend gewandelt. Ãœber 40 Prozent der Superman-EinsÃ
DGAP-News: Greiffenberger AG: Deutliche Ergebniswende im Geschäftsjahr 2010 ...
DGAP-News: Greiffenberger AG / Schlagwort(e): Jahresergebnis Greiffenberger AG: Deutliche Ergebniswende im Geschäftsjahr 2010 15.04.2011 / 14:30 --------------------------------------------------------------------- Greiffenberger AG: Deutliche Ergebniswende im Geschäftsjahr 2010 - EBIT dreht
Ethos gibt Privatplatzierung in Höhe von bis zu 15 Millionen $ bekannt ...
Ethos gibt Privatplatzierung in Höhe von bis zu 15 Millionen $ bekannt Vancouver, BC – 13. April 2011, Ethos Capital Corp. (das „Unternehmen“ oder „Ethos“) (TSX-V: ECC) (OTCQX: ETHOF) (FRANKFURT: 1ET) freut sich bekannt zu geben, dass es
DGAP-News: InnoTec TSS AG: InnoTec TSS Gruppe erzielt Umsatz- und Ergebnisrekord ...
DGAP-News: InnoTec TSS AG / Schlagwort(e): Jahresergebnis InnoTec TSS AG: InnoTec TSS Gruppe erzielt Umsatz- und Ergebnisrekord 15.04.2011 / 13:01 --------------------------------------------------------------------- Düsseldorf: Die börsennotierte InnoTec TSS AG und ihre Konzernunternehmen blic
